• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GID
Click for more information
0.00% 0.2¢

GI DYNAMICS, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GID GID Announces US $1M Convertible Note & Warrant FinancingPRICE SENSITIVE18/03/19
GID UK NHS EndoBarrier Service Releases Final One-Year DataPRICE SENSITIVE15/03/19
GID Appendix 4G - Annual Report13/03/19
GID Appendix 4E - Preliminary Final ReportPRICE SENSITIVE28/02/19
GID GID Announces IRB Approval for EndoBarrier Pivotal TrialPRICE SENSITIVE14/02/19
GID Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
GID GID Appoints VP of Clinical and Regulatory Affairs04/01/19
GID Extension of the Maturity Date of US $5M Convertible NotePRICE SENSITIVE02/01/19
GID GID Appoints Chief Financial Officer and Company Secretary11/12/18
GID Change in substantial holding29/11/18
GID Agreement with Apollo Sugar to Study EndoBarrier in IndiaPRICE SENSITIVE28/11/18
GID Cleansing Notice - 16 November 201816/11/18
GID Appendix 3B16/11/18
GID Close of Second Tranche and Grant of Options16/11/18
GID Quarterly Activities ReportPRICE SENSITIVE15/11/18
GID Pause in TradingPRICE SENSITIVE15/11/18
GID GID Announces Correction to Results of Special Meeting01/11/18
GID Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
GID GI Dynamics Announces Results of Special Meeting30/10/18
GID GID Announces Special Meeting of the Company StockholdersPRICE SENSITIVE16/10/18
GID GI Dynamics Announces Selection of New Notified BodyPRICE SENSITIVE05/10/18
GID Becoming a substantial holder02/10/18
GID Cleansing Notice - 21 September 201821/09/18
GID Appendix 3B21/09/18
GID GI Dynamics Announces Close of First Tranche of AUD $3m21/09/18
GID GID Announces AUD $6.9m Private Placement to be CompletedPRICE SENSITIVE20/09/18
GID GI Dynamics Announces Corporate UpdatePRICE SENSITIVE21/08/18
GID GID to Provide Shareholder Update on 2018 Q2 Results15/08/18
GID Half Yearly Report and AccountsPRICE SENSITIVE15/08/18
GID GID Announces FDA Approval for EndoBarrier Pivotal TrialPRICE SENSITIVE13/08/18
GID Trading HaltPRICE SENSITIVE10/08/18
GID Appendix 4C - Quarter Ended 30 June 2018PRICE SENSITIVE31/07/18
GID ABCD Releases 1st Worldwide EndoBarrier Benefit-Risk ReportPRICE SENSITIVE09/07/18 download Created with Sketch. 173.81KB
GID NHS EndoBarrier Service Patients Maintain Treatment EffectPRICE SENSITIVE04/07/18 download Created with Sketch. 132.23KB
GID GID Closes $1.75 M Convertible Note & Warrant Financing31/05/18 download Created with Sketch. 734.99KB
GID Results of 2018 Annual Meeting of Stockholders25/05/18 download Created with Sketch. 183.17KB
GID GID 2018 Q1 Form 10-QPRICE SENSITIVE16/05/18
GID GID Announces 2018 Annual Meeting of Stockholders & Update16/05/18
GID Notice of Annual General Meeting/Proxy Form15/05/18
GID GI Dynamics appoints Company Secretary11/05/18
GID EndoBarrier Meta-Analysis Published in Diabetes Care Journal10/05/18
GID GID Announces US$1.75M Convertible Note & Warrant FinancingPRICE SENSITIVE02/05/18
GID $1.75M Financing Commitment Subject to Stockholder ApprovalPRICE SENSITIVE02/05/18
GID Appendix 4C - Quarter Ended 31 March 2018PRICE SENSITIVE30/04/18
GID Responsible Entity Appointment/Resignation20/04/18
GID Annual Report to shareholders- 4G year ending 12-31-201729/03/18
GID GID to Release 2017 Annual Report & Shareholder Update Call28/03/18
GID Change of Director's Interest Notice22/03/18
GID Change in substantial holding16/03/18
GID GI Dynamics -Placement Cleansing Notice08/03/18
GID Appendix 3B March 201808/03/18
GID GID Announces Close of Second Tranche of Placement08/03/18
GID GI Dynamics Announces Results of Adjourned Special Meeting28/02/18
GID GID Preliminary Final ReportPRICE SENSITIVE27/02/18
GID GI Dynamics Adjournment of Special Meeting22/02/18
GID Change in substantial holding09/02/18
GID Notice of Extraordinary General Meeting/Proxy Form07/02/18
GID Appendix 4C - Quarter Ended 31 December 2017PRICE SENSITIVE31/01/18
GID GI Dynamics Inc., Placement Cleansing Notice23/01/18
GID GI Dynamics, Inc. January Presentation23/01/18
GID Appendix 3B- New Issue Announcement23/01/18
GID GID Announces Private Placement and Close of First TranchePRICE SENSITIVE23/01/18
GID GI Dynamics Provides 2017 Review And 2018 Business Outlook15/01/18
GID Company Secretary Resignation07/12/17
GID GI Dynamics Announces Change to Board of Directors24/11/17
GID GI Dynamics to Provide Corporate Update and 2017 Q3 Results20/11/17
GID GID 2017-Q3 Form 10QPRICE SENSITIVE15/11/17
GID GID Receives CE Certificate of Conformity Withdrawal NoticePRICE SENSITIVE13/11/17
GID Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
GID IKEM Study Shows Similar Outcomes Between GP & EndoBarrierPRICE SENSITIVE25/09/17
GID GI Dynamics Appoints Juliet Thompson to Board of Directors23/08/17
GID Half Year AccountsPRICE SENSITIVE15/08/17
GID GI Dynamics Welcomes New Scientific Advisory Board Members14/08/17
GID GI Dynamics to Provide Shareholder Update on 2017 Q210/08/17
GID Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
GID GID New Contract Manufacturer27/07/17
GID GI Dynamics Selects Proven Process Medical DevicesPRICE SENSITIVE26/07/17
GID Becoming a substantial holder12/07/17
GID Appendix 3B06/07/17
GID Change in substantial holding29/06/17
GID Change in substantial holding22/06/17
GID GI Dynamics Announces Additional Members to Its SAB20/06/17
GID GI Dynamics Announces $5m Convertible Note FinancingPRICE SENSITIVE16/06/17
GID ABCD Worldwide EndoBarrier Registry Data Presented at ADAPRICE SENSITIVE13/06/17
GID Corrected GID 2017 AGM Results09/06/17
GID GI Dynamics Releases EndoBarrier Re-Implantation DataPRICE SENSITIVE06/06/17
GID GI Dynamics Announces Change to Board of Directors02/06/17
GID Change of Australian Registered Office Address02/06/17
GID Results of Annual Meeting23/05/17
GID EndoBarrier Improves Glycemic Control, Induces Weight LossPRICE SENSITIVE23/05/17
GID GI Dynamics Meeting of Stockholders and Corporate Update18/05/17
GID GI Dynamics Announces EndoBarrier CE Mark SuspensionPRICE SENSITIVE18/05/17
GID Change in substantial holding18/05/17
GID GID 2017 Q1 FORM 10QPRICE SENSITIVE16/05/17
GID GI Dynamics Announces Scientific Advisory Board Members08/05/17
GID GI Dynamics Announces EndoBarrier Data Presented at DDW04/05/17
GID GI Dynamics Selects Allenby Capital to Explore AIM Listing03/05/17
GID Notice of Annual General Meeting/Proxy Form03/05/17
GID Change in substantial holding01/05/17
GID Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
GID GID Announces US $1M Convertible Note & Warrant Financing
18/03/19PRICE SENSITIVE
GID UK NHS EndoBarrier Service Releases Final One-Year Data
15/03/19PRICE SENSITIVE
GID Appendix 4G - Annual Report
13/03/19
GID Appendix 4E - Preliminary Final Report
28/02/19PRICE SENSITIVE
GID GID Announces IRB Approval for EndoBarrier Pivotal Trial
14/02/19PRICE SENSITIVE
GID Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
GID GID Appoints VP of Clinical and Regulatory Affairs
04/01/19
GID Extension of the Maturity Date of US $5M Convertible Note
02/01/19PRICE SENSITIVE
GID GID Appoints Chief Financial Officer and Company Secretary
11/12/18
GID Change in substantial holding
29/11/18
GID Agreement with Apollo Sugar to Study EndoBarrier in India
28/11/18PRICE SENSITIVE
GID Cleansing Notice - 16 November 2018
16/11/18
GID Appendix 3B
16/11/18
GID Close of Second Tranche and Grant of Options
16/11/18
GID Quarterly Activities Report
15/11/18PRICE SENSITIVE
GID Pause in Trading
15/11/18PRICE SENSITIVE
GID GID Announces Correction to Results of Special Meeting
01/11/18
GID Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
GID GI Dynamics Announces Results of Special Meeting
30/10/18
GID GID Announces Special Meeting of the Company Stockholders
16/10/18PRICE SENSITIVE
GID GI Dynamics Announces Selection of New Notified Body
05/10/18PRICE SENSITIVE
GID Becoming a substantial holder
02/10/18
GID Cleansing Notice - 21 September 2018
21/09/18
GID Appendix 3B
21/09/18
GID GI Dynamics Announces Close of First Tranche of AUD $3m
21/09/18
GID GID Announces AUD $6.9m Private Placement to be Completed
20/09/18PRICE SENSITIVE
GID GI Dynamics Announces Corporate Update
21/08/18PRICE SENSITIVE
GID GID to Provide Shareholder Update on 2018 Q2 Results
15/08/18
GID Half Yearly Report and Accounts
15/08/18PRICE SENSITIVE
GID GID Announces FDA Approval for EndoBarrier Pivotal Trial
13/08/18PRICE SENSITIVE
GID Trading Halt
10/08/18PRICE SENSITIVE
GID Appendix 4C - Quarter Ended 30 June 2018
31/07/18PRICE SENSITIVE
GID ABCD Releases 1st Worldwide EndoBarrier Benefit-Risk Report
09/07/18PRICE SENSITIVE download Created with Sketch. 173.81KB
GID NHS EndoBarrier Service Patients Maintain Treatment Effect
04/07/18PRICE SENSITIVE download Created with Sketch. 132.23KB
GID GID Closes $1.75 M Convertible Note & Warrant Financing
31/05/18 download Created with Sketch. 734.99KB
GID Results of 2018 Annual Meeting of Stockholders
25/05/18 download Created with Sketch. 183.17KB
GID GID 2018 Q1 Form 10-Q
16/05/18PRICE SENSITIVE
GID GID Announces 2018 Annual Meeting of Stockholders & Update
16/05/18
GID Notice of Annual General Meeting/Proxy Form
15/05/18
GID GI Dynamics appoints Company Secretary
11/05/18
GID EndoBarrier Meta-Analysis Published in Diabetes Care Journal
10/05/18
GID GID Announces US$1.75M Convertible Note & Warrant Financing
02/05/18PRICE SENSITIVE
GID $1.75M Financing Commitment Subject to Stockholder Approval
02/05/18PRICE SENSITIVE
GID Appendix 4C - Quarter Ended 31 March 2018
30/04/18PRICE SENSITIVE
GID Responsible Entity Appointment/Resignation
20/04/18
GID Annual Report to shareholders- 4G year ending 12-31-2017
29/03/18
GID GID to Release 2017 Annual Report & Shareholder Update Call
28/03/18
GID Change of Director's Interest Notice
22/03/18
GID Change in substantial holding
16/03/18
GID GI Dynamics -Placement Cleansing Notice
08/03/18
GID Appendix 3B March 2018
08/03/18
GID GID Announces Close of Second Tranche of Placement
08/03/18
GID GI Dynamics Announces Results of Adjourned Special Meeting
28/02/18
GID GID Preliminary Final Report
27/02/18PRICE SENSITIVE
GID GI Dynamics Adjournment of Special Meeting
22/02/18
GID Change in substantial holding
09/02/18
GID Notice of Extraordinary General Meeting/Proxy Form
07/02/18
GID Appendix 4C - Quarter Ended 31 December 2017
31/01/18PRICE SENSITIVE
GID GI Dynamics Inc., Placement Cleansing Notice
23/01/18
GID GI Dynamics, Inc. January Presentation
23/01/18
GID Appendix 3B- New Issue Announcement
23/01/18
GID GID Announces Private Placement and Close of First Tranche
23/01/18PRICE SENSITIVE
GID GI Dynamics Provides 2017 Review And 2018 Business Outlook
15/01/18
GID Company Secretary Resignation
07/12/17
GID GI Dynamics Announces Change to Board of Directors
24/11/17
GID GI Dynamics to Provide Corporate Update and 2017 Q3 Results
20/11/17
GID GID 2017-Q3 Form 10Q
15/11/17PRICE SENSITIVE
GID GID Receives CE Certificate of Conformity Withdrawal Notice
13/11/17PRICE SENSITIVE
GID Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
GID IKEM Study Shows Similar Outcomes Between GP & EndoBarrier
25/09/17PRICE SENSITIVE
GID GI Dynamics Appoints Juliet Thompson to Board of Directors
23/08/17
GID Half Year Accounts
15/08/17PRICE SENSITIVE
GID GI Dynamics Welcomes New Scientific Advisory Board Members
14/08/17
GID GI Dynamics to Provide Shareholder Update on 2017 Q2
10/08/17
GID Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
GID GID New Contract Manufacturer
27/07/17
GID GI Dynamics Selects Proven Process Medical Devices
26/07/17PRICE SENSITIVE
GID Becoming a substantial holder
12/07/17
GID Appendix 3B
06/07/17
GID Change in substantial holding
29/06/17
GID Change in substantial holding
22/06/17
GID GI Dynamics Announces Additional Members to Its SAB
20/06/17
GID GI Dynamics Announces $5m Convertible Note Financing
16/06/17PRICE SENSITIVE
GID ABCD Worldwide EndoBarrier Registry Data Presented at ADA
13/06/17PRICE SENSITIVE
GID Corrected GID 2017 AGM Results
09/06/17
GID GI Dynamics Releases EndoBarrier Re-Implantation Data
06/06/17PRICE SENSITIVE
GID GI Dynamics Announces Change to Board of Directors
02/06/17
GID Change of Australian Registered Office Address
02/06/17
GID Results of Annual Meeting
23/05/17
GID EndoBarrier Improves Glycemic Control, Induces Weight Loss
23/05/17PRICE SENSITIVE
GID GI Dynamics Meeting of Stockholders and Corporate Update
18/05/17
GID GI Dynamics Announces EndoBarrier CE Mark Suspension
18/05/17PRICE SENSITIVE
GID Change in substantial holding
18/05/17
GID GID 2017 Q1 FORM 10Q
16/05/17PRICE SENSITIVE
GID GI Dynamics Announces Scientific Advisory Board Members
08/05/17
GID GI Dynamics Announces EndoBarrier Data Presented at DDW
04/05/17
GID GI Dynamics Selects Allenby Capital to Explore AIM Listing
03/05/17
GID Notice of Annual General Meeting/Proxy Form
03/05/17
GID Change in substantial holding
01/05/17
GID Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.